INCRETIN MIMETICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Incretin Mimetics Market Size and Trends

The incretin mimetics market is estimated to be valued at USD 22.7 Bn in 2024 and is expected to reach USD 31.5 Bn by 2031, growing at a compound annual growth rate (CAGR) of 4.8% from 2024 to 2031.

To learn more about this report, Request sample copy

This class of drugs helps control blood sugar levels in patients with type 2 diabetes by mimicking the effects of incretin hormones like GLP-1. These medications stimulate insulin secretion and inhibit glucagon secretion in a glucose-dependent manner.

The market’s growth is driven by the rising global prevalence of diabetes. Incretin mimetics reduce cardiovascular risks and promote weight loss, offering an effective treatment option for overweight patients with diabetes. However, the availability of alternative drug classes and cost concerns could restrict market growth to some extent in the forecast period.

Rising prevalence of diabetes

The global prevalence of diabetes has been steadily rising. According to the IDF Diabetes Atlas, in 2021, over 537 million adults (20-79 years old) were living with diabetes. This number is predicted to rise to 643 million by 2030 and 783 million by 2045. While Type 2 diabetes accounts for the majority of diabetes cases worldwide, the incidence of Type 1 diabetes is also increasing at an alarming rate. The rising global burden of diabetes has major public health and economic repercussions. Not only does diabetes significantly increase the risk of debilitating and potentially fatal medical complications such as heart disease, stroke, kidney failure, blindness and lower limb amputations, but it also leads to tremendous direct healthcare costs and indirect costs related to lost productivity and work absenteeism. With the number of diabetes cases continuing to grow each year across all regions of the world, there is heightened awareness about the importance of glucose control in diabetes management and the need for advanced therapeutic options. More physicians and patients are recognizing the value of newer anti-diabetic drugs like incretin mimetics that can help improve glycemic control with a lower risk of hypoglycemia and weight gain compared to older drug classes.

To learn more about this report, Request sample copy

Growing awareness of benefits of incretin mimetics

With incretin mimetics having been on the market for over a decade, there is significant awareness within the medical community as well as among patients about the clinical profile and advantages of this class of anti-diabetes drugs. Extensive clinical research has demonstrated the ability of incretin mimetics to reduce HbA1c levels while minimizing the risks of hypoglycemia and weight gain that are commonly associated with other glucose-lowering medications. Post-marketing studies have also established their cardiovascular safety. These key benefits compared to older drugs have generated much interest among physicians who prefer to initiate patients on incretin mimetics as first-line injectable therapy when oral drugs are not sufficient. Additionally, the risk and complications associated with hyperglycemia and poorly controlled diabetes are now better appreciated by patients. They are more proactively involved in managing their condition and open to therapies that can help achieve optimal glucose control safely.